Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand ...

Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as anti-tumor necrosis factor (TNF) agents, anti-integrin agents, interleukin ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for ...

As part of the Most Favored Nation pricing effort, Pfizer has agreed to invest in U.S. manufacturing and to allow access to its drugs at a discount through a new direct-to-patient website.

The deuterated form of deupirfenidone produced favorable results in an open-label extension study. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease marked by irreversible ...

An expert discusses how primary and secondary prevention differ in atherosclerotic cardiovascular disease, with secondary prevention targeting patients who have already had events such as heart ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

We’ll be back on Monday morning with more fresh content!